Novartis AG (NVS)
| Market Cap | 290.89B +34.4% |
| Revenue (ttm) | 56.67B +9.6% |
| Net Income | 13.98B +17.1% |
| EPS | 7.15 +21.8% |
| Shares Out | 1.91B |
| PE Ratio | 20.80 |
| Forward PE | 17.40 |
| Dividend | $3.08 (2.03%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 1,070,220 |
| Open | 151.55 |
| Previous Close | 149.73 |
| Day's Range | 150.75 - 152.54 |
| 52-Week Range | 104.93 - 170.46 |
| Beta | 0.52 |
| Analysts | Hold |
| Price Target | 144.00 (-5.24%) |
| Earnings Date | Apr 28, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $144.0, which is a decrease of -5.24% from the latest price.
News
Better Pharma Dividend Stock: Novartis vs. Merck
Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.
Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs
BOSTON--(BUSINESS WIRE)--Instem announces the appointment of Szczepan Baran, VMD, MS, as Chief Scientific Officer to lead Instem's scientific and AI strategy.
Big Pharma Deepens AI Ties. What It Means For Novo, Novartis.
Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday.
Anthropic Expands Board with Novartis CEO Amid IPO Plans
Anthropic Expands Board with Novartis CEO Amid IPO Plans
Novartis Partners with OpenAI to Enhance AI Integration in Pharma
Novartis Partners with OpenAI to Enhance AI Integration in Pharma
Anthropic Adds Novartis CEO to Board
The startup behind the popular Claude chatbot and coding tool is eyeing a potential IPO as soon as this year.
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Basel, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as publ...
PPH, NVS, SNY, NVO: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the VanEck Pharmaceutical ETF (Symbol: PPH) where we have detected an appr...
Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy
Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy
Novartis: Fabhalta Cut Kidney Function Decline By 49.3% In IgAN
(RTTNews) - Novartis (NVS) reported final two-year results from its Phase 3 APPLAUSE IgAN study, showing that Fabhalta (iptacopan) slowed the decline in kidney function by 49.3% compared with placebo....
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically...
Novartis Agrees Up to $2B Excellergy Deal Amid Generic Pressure
Novartis Agrees Up to $2B Excellergy Deal Amid Generic Pressure
Novartis To Acquire Excellergy, Expanding Allergy Leadership
(RTTNews) - Novartis AG (NVS) has agreed to acquire Excellergy, Inc., a privately held biotech company developing next-generation anti-IgE therapies for allergic diseases.
Novartis to pay up to US$2 billion for US biotech firm Excellergy
Swiss drugmaker Novartis will buy California-based biotech company Excellergy in a deal worth up to US$2 billion, it said on Friday, extending its anti-allergy range and in line with plans to increase...
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring...
Novartis Expands Pipeline With $2 Billion Biotech Deal
Novartis Expands Pipeline With $2 Billion Biotech Deal
Novartis to Buy Biotech Excellergy for Up to $2 Billion
Novartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
Swiss pharma company Novartis said on Friday it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion.
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction...
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism desi...
Novartis (NVS) Receives New Price Target from Morgan Stanley | NVS Stock News
Novartis (NVS) Receives New Price Target from Morgan Stanley | NVS Stock News
Sarepta Surges As It Takes On Novartis' $12 Billion Muscular Dystrophy Buyout
Sarepta stock popped Wednesday after the company reported promising results for its gene-silencing tech in two forms of muscular dystrophy.
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year's American Academy of Dermatology (AAD) Annual Meeting.
Novartis Agrees Up to $3 Billion Synnovation Breast Cancer Drug Deal
Novartis Agrees Up to $3 Billion Synnovation Breast Cancer Drug Deal
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potent...